Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)

• Published in: Oncology letters 2023-09, Vol.26 (3), p.1, Article 372
• Main Authors: Wei, Chun, Lan, Xiaojun, Qiu, Maona, Cui, Ran, Fu, Qiuxia, Shinge, Shafiu A. Umar, Muluh, Tobias Achu, Jiang, Ou
• Format: Article
• Language: English
• Subjects: Alcohol; Apoptosis; Biomarkers; Cancer; Cancer therapies; Cell cycle; Chemotherapy; Exocrine glands; Genetic aspects; Head & neck cancer; Head and neck cancer; Human papillomavirus; Immune response; Immune system; Immunotherapy; Larynx; Medical prognosis; Metastasis; Oncology; Papillomavirus infections; Pathogenesis; Patients; Radiation therapy; Review; Risk factors; Squamous cell carcinoma; Surgeons; Surgery; Tobacco; Tumors
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2023.13958

Immunotherapy has become one of the most promising approaches in tumor therapy, and there are numerous associated clinical trials in China. As an immunosuppressive tumor, head and neck squamous cell carcinoma (HNSCC) carries a high mutation burden, making immune checkpoint inhibitors promising candidates in this field due to their unique mechanism of action. The present review outlines a comprehensive multidisciplinary cancer treatment approach and elaborates on how combining immunochemotherapy and immunoradiotherapy guidelines could enhance clinical efficacy in patients with HNSCC. Furthermore, the present review explores the immunology of HNSCC, current immunotherapeutic strategies to enhance antitumor activity, ongoing clinical trials and the future direction of the current immune landscape in HNSCC. Advanced-stage HNSCC presents with a poor prognosis, low survival rates and minimal improvement in patient survival trends over time. Understanding the potential of immunotherapy and ways to combine it with surgery, chemotherapy and radiotherapy confers good prospects for the management of human papillomavirus (HPV)-positive HNSCC, as well as other HPV-positive malignancies. Understanding the immune system and its effect on HNSCC progression and metastasis will help to uncover novel biomarkers for the selection of patients and to enhance the efficacy of treatments. Further research on why current immune checkpoint inhibitors and targeted drugs are only effective for some patients in the clinic is needed; therefore, further research is required to improve the overall survival of affected patients. Key words: head and neck cancer, immunotherapy, human papillomavirus, immune response, biomarkers, immune checkpoint inhibitors